Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

114.64 -13.14 (-10.29%)
Streaming Delayed Price Updated: 11:06 AM EDT, Jul 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
69 70 Next >
20 Dividend Growth Stocks For Faster Growth And Profit
The equal weight growth model was willing to accept faster-growing companies with lower current dividend yields, but faster-growing dividends. 
Via Talk Markets
BioNTech Stock Gets Upgrade, Analyst Sees Multiple Upside Opportunities
Via Benzinga
Elon Musk Dumps Another $3.6B Tesla Stock, Facebook's Jobs' Feature To Disappear Next Year, Foxconn Relaxes Covid Restrictions In China Factory: Today's Top Stories
Benzinga Elon Musk Dumps Another $3.6 Billion Of Tesla Stock 
Via Benzinga
2 Dividend Stocks to Buy and Hold Through 2023 and Beyond
These pharma giants are crushing the broader market this year. 
Via The Motley Fool
Why Moderna Stock Is Popping Over 20% Today
Moderna Stock is ripping higher today after a cancer treatment breakthrough. Is Moderna stock a buy now? 
Via The Motley Fool
Why Moderna Stock Is Skyrocketing Today
Moderna's personalized cancer vaccine program just received a big boost. 
Via The Motley Fool
Here's How Much $100 Invested In Merck & Co 5 Years Ago Would Be Worth Today
Via Benzinga
West Africa-Based Studies Show JNJ, Merck's Ebola Vaccines Provide Lasting Antibodies
Via Benzinga
The Best ETF For Dividend Yield And Dividend Growth
This ETF checks off all the boxes in terms of performance, dividend growth, and solid yield. 
Via The Motley Fool
FDA Extends Review Period For AstraZeneca-Merck Partnered Cancer Drug, Lynparza
Via Benzinga
Is Moderna a Good Stock to Buy Right Now?
Recent results suggest the company's cancer vaccine candidate can succeed where others have failed. 
Via The Motley Fool
Finding 20 Dividend Growth Stocks In A Bad Market
Starting in 2012, it became more and more difficult for prudent dividend growth stock investors looking for income. The stock market was trading at excessive valuations, and interest rates were at... 
Via Talk Markets
Moderna Stock Shows Surprising Strength; Key Rating Upgraded
See if Moderna stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day average. 
Via Investor's Business Daily
7 Stocks to Buy on the Dip as the S&P 500 Falters
Investors looking for a margin of safety and growth even in a recession should consider these cheap stocks to buy on the dip. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Is Moderna Stock a Buy After Its Impressive Cancer Vaccine Results?
Moderna could have a winner with its personalized cancer vaccine. But the company also faces big questions. 
Via The Motley Fool
Market Volatility Drops Sharply Ahead Of Fed's Rate Decision
US stocks closed higher on Tuesday, after the recent data showed the smallest annual rise in inflation in around one year. The consumer price index rose 0.1% in November following a 0.4% increase in... 
Via Benzinga
Tesla, Amazon, Coinbase, Moderna, Nuwellis: Why These 5 Stocks Are Drawing Investors' Attention Today
Major Wall Street indices closed in the green on Tuesday after consumer price inflation at 7.1% for November came in lower than expected. 
Via Benzinga
Moderna Soars On Cancer Vaccine News: Here's What To Watch Going Forward
Moderna, Inc (NASDAQ: MRNA) gapped up 13% to start the trading day on Tuesday and was skyrocketing an additional 12% intraday after announcing that its Merck & Co, Inc (NYSE: MRK) partnered cancer 
Via Benzinga
The 7 Best Investment Funds to Navigate a Possible Recession
With a possible recession on the horizon, investors may be able to protect themselves through the best investment funds. 
Via InvestorPlace
Moderna's Data From Personalized Cancer Vaccine Provides Relief To Investors, Analyst Says
Via Benzinga
2 Nasdaq Stocks Taking Big Strides Forward
As markets soar following a healthy inflation report, investors are watching these two companies closely. 
Via The Motley Fool
Moderna (MRNA) Stock Soars on Cancer Vaccine News
Moderna (MRNA) stock is rising higher on Tuesday following the release of data from a Phase 2B cancer vaccine clinical trial. 
Via InvestorPlace
Moderna-Merck Partnered Cancer Vaccine Meets Primary Efficacy Endpoint, Stock Jumps
Via Benzinga
Why Merck's $250 Million Investment In Moderna May Have Just Paid Off
Merck opted into Moderna's cancer vaccine. Now, the companies have Phase 2 data. 
Via Investor's Business Daily
Mirati Wins FDA Approval For Amgen-Rivaling Cancer Drug As Wild Stock Swing Continues
FDA action on its KRAS-blocking drug could help recently downtrodden Mirati. 
Via Investor's Business Daily
3 High-Flying Stocks in 2022 That Should Keep Soaring in 2023
These stocks' tailwinds should continue blowing in the new year. 
Via The Motley Fool
Cloud Stocks: Veeva CRM Will Move To Vault Platform
Veeva will be focusing on Vault CRM for pharma and biotech, where it has the broadest portfolio. 
Via Talk Markets
Stryker, Freeport-McMoRan, Southwest Gas And This Health Care Major Feature On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Brenda Vingiello of Sand Hill Global Advisors chose Stryker Corporation (NYSE: SYK), saying all medical procedures that 
Via Benzinga
Why Shares of Mirati Therapeutics Fell Wednesday
The company presented phase 2 data from its non-small cell lung cancer therapy. 
Via The Motley Fool
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
69 70 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.